NCT04948242: GETCOV-2

Characteristics of Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (COVID-19)

Status unknown Last updated 20 April 2023

What this trial tests

trial in SARS-CoV2 Infection in 5,000 participants. Status unknown.

Timeline

12 December 2019

Primary endpoint
17 April 2023

31 December 2023

Quick facts

Lead sponsor	Hospital Universitari Joan XXIII de Tarragona.
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	5,000
Start date	12 December 2019
Primary completion	17 April 2023
Estimated completion	31 December 2023
Sites	1 location across Spain

Conditions studied

• SARS-CoV2 Infection — all drugs for SARS-CoV2 Infection →

Sponsor

Hospital Universitari Joan XXIII de Tarragona.

Who can join

16 and older, any sex, with SARS-CoV2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A multicenter observational, prospective cohort study that consisted of a large-scale data source of hospital ICU admissions and patient-level clinical data in Spain.

The main objective is to develop a national database belonging to SEMICYUC (Spanish Society of Critical Care) to describe epidemiological and clinical characteristics and risk factors related to ICU mortality in critically ill patients admitted to ICU due to severe COVID-19 in Spain.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Mortality comparison between the first and second/third waves among 3,795 critical COVID-19 patients with pneumonia admitted to the ICU: A multicentre retrospective cohort study.
   Carbonell R, Urgelés S, Rodríguez A, Bodí M, et al · · 2021 · cited 122× · PMID 34751263 · DOI 10.1016/j.lanepe.2021.100243
2. Negative predictive value of procalcitonin to rule out bacterial respiratory co-infection in critical covid-19 patients.
   Carbonell R, Urgelés S, Salgado M, Rodríguez A, et al · · 2022 · cited 28× · PMID 35781017 · DOI 10.1016/j.jinf.2022.06.024
3. Dexamethasone as risk-factor for ICU-acquired respiratory tract infections in severe COVID-19.
   Reyes LF, Rodriguez A, Bastidas A, Parra-Tanoux D, et al · · 2022 · cited 28× · PMID 35217370 · DOI 10.1016/j.jcrc.2022.154014
4. Corticosteroid treatment and mortality in mechanically ventilated COVID-19-associated acute respiratory distress syndrome (ARDS) patients: a multicentre cohort study.
   Moreno G, Carbonell R, Martin-Loeches I, Solé-Violán J, et al · · 2021 · cited 23× · PMID 34825976 · DOI 10.1186/s13613-021-00951-0
5. Timing of intubation and ICU mortality in COVID-19 patients: a retrospective analysis of 4198 critically ill patients during the first and second waves.
   Manrique S, Claverias L, Magret M, Masclans JR, et al · · 2023 · cited 22× · PMID 37106321 · DOI 10.1186/s12871-023-02081-5
6. A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients.
   Moreno G, Ruiz-Botella M, Martín-Loeches I, Gómez Álvarez J, et al · · 2023 · cited 6× · PMID 34720310 · DOI 10.1016/j.medin.2021.10.002
7. A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients.
   Moreno G, Ruiz-Botella M, Martín-Loeches I, Gómez Álvarez J, et al · · 2023 · cited 4× · PMID 36272908 · DOI 10.1016/j.medine.2021.10.016
8. Machine Learning-Based Identification of Risk Factors for ICU Mortality in 8902 Critically Ill Patients with Pandemic Viral Infection.
   Papiol E, Ferrer R, Ruiz-Rodríguez JC, Díaz E, et al · · 2025 · cited 1× · PMID 40807005 · DOI 10.3390/jcm14155383